Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 6c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.72), $0.06 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $13.53 million versus the consensus estimate of $11.41 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Benchmark Reiterates Buy Rating on Malibu Boats (MBUU) on Significant Earnings Upside
• Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance